| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hongxin Dong, Cynthia A Csernansky, Maureen V Martin, Amy Bertchume, Dana Vallera, John G Csernansk. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology. vol 181. issue 1. 2006-04-10. PMID:15778881. |
acetylcholinesterase inhibitors are widely used for the treatment of patients with alzheimer's disease (ad). |
2006-04-10 |
2023-08-12 |
mouse |
| J Birk. Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database of systematic reviews. issue 1. 2006-04-07. PMID:16437532. |
since the introduction of the first cholinesterase inhibitor (chei) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate alzheimer's disease.the drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. |
2006-04-07 |
2023-08-12 |
Not clear |
| Michael J O'Neil. SMi 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease. Expert opinion on investigational drugs. vol 13. issue 10. 2006-04-06. PMID:15461566. |
the major focus in the alzheimer's disease area was finding symptomatic treatments that are superior to acetylcholinesterase inhibitors and the extensive efforts that are ongoing to develop disease-modifying therapies. |
2006-04-06 |
2023-08-12 |
Not clear |
| Petra Kapková, Vildan Alptüzün, Peter Frey, Ercin Erciyas, Ulrike Holzgrab. Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. Bioorganic & medicinal chemistry. vol 14. issue 2. 2006-04-06. PMID:16198581. |
search for dual function inhibitors for alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their abeta fibril formation inhibition capacity. |
2006-04-06 |
2023-08-12 |
Not clear |
| Edward G Shaw, Robin Rosdhal, Ralph B D'Agostino, James Lovato, Michelle J Naughton, Michael E Robbins, Stephen R Rap. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. vol 24. issue 9. 2006-04-04. PMID:16549835. |
a prospective, open-label phase ii study was conducted to determine whether donepezil, a us food and drug administration-approved reversible acetylcholinesterase inhibitor used to treat mild to moderate alzheimer's type dementia, improved cognitive functioning, mood, and quality of life (qol) in irradiated brain tumor patients. |
2006-04-04 |
2023-08-12 |
Not clear |
| David S Geldmache. Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert review of neurotherapeutics. vol 4. issue 1. 2006-03-29. PMID:15853610. |
at current, the standard of care for patients with mild and moderately severe alzheimer's disease includes the use of acetylcholinesterase inhibitors. |
2006-03-29 |
2023-08-12 |
Not clear |
| David E Kuhl, Robert A Koeppe, Scott E Snyder, Satoshi Minoshima, Kirk A Frey, Michael R Kilbour. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Annals of neurology. vol 59. issue 1. 2006-03-23. PMID:16278840. |
we tested the premise that cholinesterase inhibitor therapy should target butyrylcholinesterase (buche) in alzheimer's disease (ad), not acetylcholinesterase (ache) alone, because both enzymes hydrolyze acetylcholine, and buche is increased in ad cerebral cortex. |
2006-03-23 |
2023-08-12 |
Not clear |
| Kristin Huse Haug, Inger Lise Bogen, Harald Osmundsen, Ivar Walaas, Frode Fonnu. Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. Neurochemical research. vol 30. issue 12. 2006-03-21. PMID:16362770. |
donepezil is a selective inhibitor of acetylcholinesterase (ache) clinically used for treating alzheimer's disease. |
2006-03-21 |
2023-08-12 |
human |
| b' Mar\\xc3\\xada Isabel Rodr\\xc3\\xadguez-Franco, Mar\\xc3\\xada Isabel Fern\\xc3\\xa1ndez-Bachiller, Concepci\\xc3\\xb3n P\\xc3\\xa9rez, Blanca Hern\\xc3\\xa1ndez-Ledesma, Bego\\xc3\\xb1a Bartolom\\xc3\\xa. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. Journal of medicinal chemistry. vol 49. issue 2. 2006-03-21. PMID:16420031.' |
novel tacrine-melatonin hybrids as dual-acting drugs for alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. |
2006-03-21 |
2023-08-12 |
human |
| H van den Bussch. [Questions and theses of pharmacological therapeutic options of Alzheimer's dementia with acetylcholinesterase inhibitors]. Zeitschrift fur Gerontologie und Geriatrie. vol 38 Suppl 1. 2006-03-14. PMID:16189731. |
[questions and theses of pharmacological therapeutic options of alzheimer's dementia with acetylcholinesterase inhibitors]. |
2006-03-14 |
2023-08-12 |
Not clear |
| Allan T Gulledge, Greg J Stuar. Cholinergic inhibition of neocortical pyramidal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 44. 2006-03-13. PMID:16267239. |
furthermore, eserine, an acetylcholinesterase inhibitor similar to those used therapeutically in the treatment of alzheimer's disease, disproportionately enhanced the excitatory actions of acetylcholine while reducing the ability of acetylcholine to generate inhibitory responses during repeated applications of ach. |
2006-03-13 |
2023-08-12 |
rat |
| J M Rollinger, P Mocka, C Zidorn, E P Ellmerer, T Langer, H Stuppne. Application of the in combo screening approach for the discovery of non-alkaloid acetylcholinesterase inhibitors from Cichorium intybus. Current drug discovery technologies. vol 2. issue 3. 2006-03-10. PMID:16472227. |
because of the direct correlation of cholinergic deficit and the severity of dementia, alzheimer's disease is preferentially treated with acetylcholinesterase (ache) inhibitors to supplement the acetylcholine level. |
2006-03-10 |
2023-08-12 |
Not clear |
| D Muñoz-Torrero, P Camp. Dimeric and hybrid anti-Alzheimer drug candidates. Current medicinal chemistry. vol 13. issue 4. 2006-03-10. PMID:16475930. |
as a consequence of their capability to simultaneously interact with two binding sites of the same biological target (the enzyme acetylcholinesterase in most cases), to expand their interaction in the main binding site of the target molecule, or to interact with two different biological targets of interest in the pathogenesis of the disease, these dimeric or hybrid compounds exhibit an improved pharmacological profile including high affinity interactions, additional non conventional actions or complementary actions, what makes them potential drug candidates for the treatment of alzheimer's disease. |
2006-03-10 |
2023-08-12 |
Not clear |
| Gerald H Lushington, Jian-Xin Guo, Margaret M Hurle. Acetylcholinesterase: molecular modeling with the whole toolkit. Current topics in medicinal chemistry. vol 6. issue 1. 2006-03-02. PMID:16454758. |
molecular modeling efforts aimed at probing the structure, function and inhibition of the acetylcholinesterase enzyme have abounded in the last decade, largely because of the system's importance to medical conditions such as myasthenia gravis, alzheimer's disease and parkinson's disease, and well as its famous toxicological susceptibility to nerve agents. |
2006-03-02 |
2023-08-12 |
Not clear |
| Kala M Mehta, Maggie Yin, Cynthia Resendez, Kristine Yaff. Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology. vol 65. issue 1. 2006-02-24. PMID:16009909. |
ethnic differences in acetylcholinesterase inhibitor use for alzheimer disease. |
2006-02-24 |
2023-08-12 |
Not clear |
| Kala M Mehta, Maggie Yin, Cynthia Resendez, Kristine Yaff. Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease. Neurology. vol 65. issue 1. 2006-02-24. PMID:16009909. |
acetylcholinesterase inhibitors (achis) have been demonstrated to improve alzheimer disease symptoms. |
2006-02-24 |
2023-08-12 |
Not clear |
| Paul T Franci. The interplay of neurotransmitters in Alzheimer's disease. CNS spectrums. vol 10. issue 11 Suppl 18. 2006-02-24. PMID:16273023. |
this deficit and other presynaptic cholinergic deficits, including loss of cholinergic neurons and decreased acetylcholinesterase activity, underscore the cholinergic hypothesis of alzheimer's disease. |
2006-02-24 |
2023-08-12 |
Not clear |
| Michal Harel, Janice L Hyatt, Boris Brumshtein, Christopher L Morton, Randy M Wadkins, Israel Silman, Joel L Sussman, Philip M Potte. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. Chemico-biological interactions. vol 157-158. 2006-02-24. PMID:16289500. |
the 2.6 angstroms resolution crystal structure of its complex with torpedo californica acetylcholinesterase (tcache) demonstrates that cpt-11 binds to tcache and spans its gorge similarly to the alzheimer drug, aricept. |
2006-02-24 |
2023-08-12 |
Not clear |
| Ai-Ling Fu, Xing-Mei Zhang, Man-Ji Su. Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice. Brain research. vol 1066. issue 1-2. 2006-02-15. PMID:16337925. |
antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in alzheimer's disease model mice. |
2006-02-15 |
2023-08-12 |
mouse |
| Ai-Ling Fu, Xing-Mei Zhang, Man-Ji Su. Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice. Brain research. vol 1066. issue 1-2. 2006-02-15. PMID:16337925. |
to examine whether the selected antisense oligodeoxynucleotides (as-odn) targeting against human brain acetylcholinesterase (ache) mrna could improve the cognitive deficit in the alzheimer's disease (ad) model mice induced by amyloid-beta peptide (abeta), we determined the time-effect relationship of ache activity and the learning and memory after as-odn delivery. |
2006-02-15 |
2023-08-12 |
mouse |